Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF May 6, 2016 | Archived Issues

Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - May 2016 (PDF)  


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Changes in Warnings, Labels for Aripiprazole, Metformin, Fluconazole, Brintellix

Pharmacy Focus

The U.S. Food and Drug Administration issued a warning regarding reports of impulse-control issues with the use of aripiprazole. Also, the FDA has revised the labeling for metformin and is evaluating a study that shows there is a possible increased risk of miscarriage with the use of oral fluconazole. And the agency has approved the name change of the antidepressant Brintellix to Trintellix.

FDA: Impulse-Control Problems Possible With Aripiprazole

The FDA issued a warning regarding reports of impulse-control issues (urges to binge eat, shop, gamble and have sex) with the use of the antipsychotic aripiprazole. These uncontrollable urges were reported to have stopped when the medicine was discontinued or the dose was reduced.

The FDA is recommending that healthcare providers alert patients and caregivers of these potential effects. Prescribers should consider reducing the dose or stopping the medication if patients develop these compulsive behaviors.

The FDA website has more information.

FDA Revises Metformin Warnings for Patients With Reduced Kidney Function

The FDA has revised the labeling for metformin regarding patients with impaired renal function.

The FDA concluded, from its review of studies published in the medical literature, that metformin can be used safely in patients with mild impairment in kidney function and in some patients with moderate impairment in kidney function. FDA is requiring changes to the metformin labeling to reflect this new information and provide specific recommendations on the drug's use in patients with mild to moderate kidney impairment.

The FDA website has more information.

FDA Evaluating Use of Oral Fluconazole in Pregnancy

The FDA is evaluating a study that shows there is a possible increased risk of miscarriage with the use of oral fluconazole (Diflucan) for yeast infections.

Until FDA's review is complete and more is understood about this study and other available data, FDA advises cautious prescribing of oral fluconazole in pregnancy.

The FDA website has more information.

Brintellix Changes Name to Trintellix to Avoid Confusion With Brilinta

The FDA has approved the name change of the antidepressant Brintellix to Trintellix to avoid confusion with Brilinta (ticagrelor). Prescribers are advised to include generic names to avoid confusion in the interim. Trintellix tablets will look the same as the previously named Brintellix tablets but will have a new NDC number.

The FDA website has more information.